CompletedPhase 1

A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake

A Dose-response Study of the Effects of Exendin-9,39 on Gastrointestinal Symptoms and Food Intake.

Lead sponsor

Mayo Clinic

Asset

Avexitide

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02128581

Org study ID14-002150

Secondary IDR01DK082396

Secondary IDUL1RR024150

Timeline

Milestones

Study first posted2014-05-01estimated

Last update posted2019-10-23actual

Study start2014-05 (month precision)

Primary completion2016-03actual (month precision)

Study completion2019-07actual (month precision)

Assets

Investigational agents

Avexitide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age20 Years

Maximum age70 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subjects who have undergone Roux en-Y Gastric Bypass at least 6 months prior to enrollment in the study.

•Subjects without active systemic illness.

Exclusion criteria

•Subjects <20 years of age will not be studied to minimize the possibility of type 1 diabetes.

•Subjects >70 years of age will not be studied to minimize the potential confounding effects of age on glucose tolerance.

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.